Results 211 to 220 of about 22,483 (254)

The incidence of paroxysmal nocturnal hemoglobinuria cell clones in the Nordic countries. [PDF]

Ann Hematol
Pedersen TH, Tjønnfjord E, Korkama ES, Vikman M, Ahmadi A, Overgaard UM, Kjellander C.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Journal of Clinical Oncology, 2022
PURPOSE Secondary myeloid neoplasms (sMNs) remain the most serious long-term complications in patients with aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH).
C. Gurnari, S. Pagliuca, P. Prata, J. Galimard, L. F. B. Catto, L. Larcher, M. Sébert, V. Allain, B. Patel, Arda Durmaz, A. Pinto, M. Inacio, L. Hernandez, N. Dhédin, S. Caillat-Zucman, E. Clappier, F. Sicre de Fontbrune, M. Voso, V. Visconte, R. Peffault de Latour, J. Soulier, R. Calado, G. Socié, J. Maciejewski   +23 more
semanticscholar   +1 more source

Paroxysmal nocturnal hemoglobinuria

Hématologie, 2013
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cells. PNH is related to a somatic mutation in the phosphatidylinositol glycan class A (PIG-A), X-linked gene, responsible for a deficiency in glycosylphosphatidylinositol-anchored proteins (GPI-AP).
R, Peffault de Latour, Z, Amoura, G, Socié   +2 more
openaire   +2 more sources

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.

New England Journal of Medicine
BACKGROUND Persistent hemolytic anemia and a lack of oral treatments are challenges for patients with paroxysmal nocturnal hemoglobinuria who have received anti-C5 therapy or have not received complement inhibitors.
R. Peffault de Latour, Alexander Röth, A. Kulasekararaj, Bing Han, Phillip Scheinberg, Jaroslaw P Maciejewski, Yasutaka Ueda, C. de Castro, Eros Di Bona, Rong Fu, Li Zhang, Morag Griffin, Saskia M C Langemeijer, J. Panse, H. Schrezenmeier, W. Barcellini, Vitor A Q Mauad, Philippe Schafhausen, S. Tavitian, Eloise Beggiato, L. Chew, A. Gaya, Wei-Han Huang, Jun Ho Jang, Toshio Kitawaki, Abdullah Kutlar, Rosario Notaro, Vinod Pullarkat, Jörg Schubert, Louis Terriou, Michihiro Uchiyama, Lily Wong Lee Lee, E. Yap, F. Sicre de Fontbrune, L. Marano, F. Alashkar, Shreyans Gandhi, Roochi Trikha, Chen Yang, Hui Liu, Richard J. Kelly, B. Höchsmann, Cécile Kerloeguen, Partha Banerjee, R. Levitch, Rakesh Kumar, Zhixin Wang, Christine Thorburn, Samopriyo Maitra, Shujie Li, Aurelie Verles, M. Dahlke, A. Risitano   +52 more
semanticscholar   +1 more source

Real‐world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria

American journal of hematology/oncology
Pegcetacoplan significantly improves outcomes for patients with paroxysmal nocturnal hemoglobinuria (PNH) experiencing extravascular hemolysis (EVH) on eculizumab, leading to approval in 2021/2022 (USA/Europe).
Morag Griffin, Richard J. Kelly, Isabelle Brindel, Lynda Maafa, Roochi Trikha, Petra Muus, T. Munir, A. Varghese, Lindsay D Mitchell, S. Nagumantry, Shreyans Gandhi, A. Pike, A. Kulasekararaj, R. Peffault de Latour   +13 more
semanticscholar   +1 more source

Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment

International Journal of Molecular Sciences
Paroxysmal Nocturnal Hemoglobinuria (PNH) constitutes a rare bone marrow failure syndrome characterized by hemolytic anemia, thrombotic events (TEs), and bone marrow aplasia of variable degrees.
Styliani Kokoris, Antri Polyviou, Paschalis Evangelidis, E. Grouzi, S. Valsami, Konstantinos Tragiannidis, A. Gialeraki, Dimitrios A. Tsakiris, E. Gavriilaki   +8 more
semanticscholar   +1 more source